I am BIO Podcast

YOU asked, and we answered. In this episode, we had our experts on standby to answer questions from you, our listeners. We discuss topics ranging from the safety of genetically modified foods (GMOs), to the new era of personalized medicine, feeding the world by 2050, and even what makes start-up companies attractive to investors.

Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies.

Talking about women’s health has been a taboo subject for some time, contributing to a lack of innovation in the sector. Still today, many are uncomfortable discussing the topic. Consequently, only 2% of medical products in the pipeline are for women’s health and only 2% of all venture capital dollars go into developing these products. In this episode, we talk with two women in biotech who are trying to change that narrative and infuse more investment in innovations that meet the needs of half the population.

Current market trends have put investors in a “flight-to-safety” mentality, especially when it comes to biotech companies. What does this mean for getting biotech innovations to the marketplace? This episode explores the daunting challenge of raising capital in a bear market.